Pharma Focus Europe

Charles River Laboratories Acquires SAMDI Tech

Tuesday, January 31, 2023

Charles River Laboratories International, Inc., announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition marks the culmination of a partnership between the companies that began in 2018.

Based in Chicago, Illinois, SAMDI Tech offers a proprietary mass spectrometry (MS) technology for high-throughput analysis of biochemical activities and affinity selection MS (SAMDI ASMS) for identifying binding interactions. The technology minimizes false positive results, reduces reagent requirements, and offers multiplexing capabilities without restricting assay conditions. These solutions are increasingly favored by clients to accelerate the timeline and reduce costs to identify a lead drug candidate, drive more effective research and high-quality scientific data, and enable clients to make critical go-no-go decisions earlier and advance their projects more efficiently. SAMDI Tech’s comprehensive drug discovery solutions also include optical and radioactivity capabilities, cell-based assays, and an in-house collection of over a half million drug-like small molecules.

The combination of Charles River’s end-to-end portfolio and industry-leading scientific expertise with SAMDI Tech’s innovative MS technology and expertise in assay solutions has the potential to significantly accelerate and augment clients’ discovery efforts by measuring biochemical activities and identifying binding interactions for virtually any small molecule drug target. The acquisition will provide Charles River’s clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, industry-leading library of drug discovery solutions.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “The acquisition of SAMDI Tech’s cutting-edge, high-throughput screening technology further strengthens Charles River’s drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients’ early-stage research. SAMDI Tech’s platform combined with our premier, end-to-end drug discovery portfolio will generate better data and faster hit identification and is another step to accelerate our clients’ drug discovery efforts. With over a decade of industry experience and the successful, existing partnership, we believe the addition of SAMDI Tech will continue to generate new business opportunities and we are pleased to welcome them to the Charles River family.”

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024